An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Introduction: Ulcerative colitis (UC) is a chronic inflammatory condition of the gastrointestinal tract involving a dysregulated immune response. Sphingosine-1-phosphate (S1P) is involved in immune cell regulation. S1P-receptor modulators, such as ozanimod, inhibit lymphocyte migration and have therapeutic potential in UC. Areas covered: Ozanimod is the first S1P-receptor modulator approved for the treatment of UC. It acts as a functional antagonist, causing internalization of S1P receptors on T-cells. Lymphocyte egress from lymph nodes is inhibited, and migration to sites of active inflammation is curtailed. There are several S1P-receptor subtypes, present in various organs, which inform understanding of ozanimod’s side-effect profile including bradycardia and macular edema. In this review, the authors discuss the mechanism of action, pharmacokinetics, clinical efficacy, and safety profile of ozanimod in the treatment of patients with moderate-to-severe UC. Expert opinion: The S1P-receptor modulator ozanimod is an oral small molecule with a rapid onset of action and a novel therapeutic mechanism in the treatment of UC. It is an effective treatment both in bio-naïve and bio-exposed patients. Although the safety profile of ozanimod looks favorable, more long-term data are needed. Further studies are required to compare ozanimod to currently available therapies to best define its positioning in UC treatment algorithms.

Original languageEnglish
Pages (from-to)893-904
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Issue number8
StatePublished - 2022


  • Inflammatory bowel disease
  • ozanimod
  • small molecules
  • sphingosine-1-phosphate receptor modulators
  • ulcerative colitis


Dive into the research topics of 'An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis'. Together they form a unique fingerprint.

Cite this